
| 1W | 1M | 6M | 1Y | 5Y | |
|---|---|---|---|---|---|
| Stock | −1.0% | +7.4% | +31.6% | +49.7% | −2.9% |
| SPY | −2.3% | −4.4% | +0.3% | +10.2% | +67.3% |
Historical total returns · Dividends reinvested
Loading…
No company summary is available right now.
New Five-Year Lecanemab Data from Clarity AD Study Long-Term Extension Presented at CTAD 2026Yahoo Finance · 22 h ago
TRIMTECH Therapeutics Enters Strategic Research Collaboration With Biogen to Advance Small Molecule Degraders for Neurodegenerative DiseaseYahoo Finance · 1 d ago
LEQEMBI® Pen (Subcutaneous Formulation of LEQEMBI®) Now Available in Japan for Patients with Early Alzheimer’s DiseaseYahoo Finance · 5 d ago